Autoimmune Programs

About Century Therapeutics

Century Therapeutics is a clinical-stage biotechnology company developing allogeneic, iPSC-derived cell therapies for oncology and autoimmunity. Its core strategy is to utilize a renewable master iPSC bank, combined with precision genetic engineering, to create standardized, scalable, and readily available therapeutic products. Key achievements include advancing its lead CNTY-101 program into Phase 1 trials for B-cell malignancies and securing strategic collaborations with Bristol Myers Squibb and Bayer. The company's long-term vision is to establish iPSC-derived cell therapies as a mainstream, accessible treatment modality.

Therapeutic Areas